My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 143

    1.

    Hypoglycemia following a nateglinide overdose in a suicide attempt.

    Nakayama S, Hirose T, Watada H, Tanaka Y, Kawamori R.

    Diabetes Care. 2005 Jan;28(1):227-8. No abstract available. PMID: 15616260 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Intentional overdose with insulin glargine.

    Ashawesh K, Padinjakara RN, Murthy NP, Nizar H, Anwar A.

    Am J Health Syst Pharm. 2009 Mar 15;66(6):534. No abstract available. PMID: 19265181 [PubMed - indexed for MEDLINE]Related articles

    3.

    Lantus overdose: case presentation and management options.

    Fuller ET, Miller MA, Kaylor DW, Janke C.

    J Emerg Med. 2009 Jan;36(1):26-9. Epub 2007 Jul 20.PMID: 17976762 [PubMed - indexed for MEDLINE]Related articles

    4.

    Poisoning with insulin glargine.

    Brvar M, Mozina M, Bunc M.

    Clin Toxicol (Phila). 2005;43(3):219-20. No abstract available. PMID: 15902802 [PubMed - indexed for MEDLINE]Related articles

    5.

    Octreotide therapy for nateglinide-induced hypoglycemia.

    Sherk DK, Bryant SM.

    Ann Emerg Med. 2007 Dec;50(6):745-6. No abstract available. PMID: 18023765 [PubMed - indexed for MEDLINE]Related articles

    6.

    Postmarketing study of nateglinide in Japan: treatment of medication-naïve patients with type 2 diabetes.

    Taki H, Maki T, Iso T, Tanabe S, Kajiura T.

    Adv Ther. 2005 Nov-Dec;22(6):621-35.PMID: 16510379 [PubMed - indexed for MEDLINE]Related articles

    7.

    Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.

    Tuomi T, Honkanen EH, Isomaa B, Sarelin L, Groop LC.

    Diabetes Care. 2006 Feb;29(2):189-94.PMID: 16443858 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats.

    Iwase M, Nakamura U, Uchizono Y, Nohara S, Sasaki N, Sonoki K, Iida M.

    Eur J Pharmacol. 2005 Aug 22;518(2-3):243-50.PMID: 16023099 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effect of decrease in both postprandial blood glucose (PBG) and fasting blood glucose (FBG) levels in normal beagle dogs with nateglinide enteric coated granules and immediate release tablets.

    Makino C, Ninomiya N, Sakai H, Orita H, Okano A, Yabuki A.

    Chem Pharm Bull (Tokyo). 2006 Apr;54(4):409-14.PMID: 16595936 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals.

    González-Ortiz M, Hernández-Salazar E, Martínez-Abundis E.

    J Diabetes Complications. 2005 Nov-Dec;19(6):356-60.PMID: 16260353 [PubMed - indexed for MEDLINE]Related articles

    11.

    Attempted suicide by massive insulin injection: a case report and review of the literature.

    Thewjitcharoen Y, Lekpittaya N, Himathongkam T.

    J Med Assoc Thai. 2008 Dec;91(12):1920-4. Review.PMID: 19133531 [PubMed - indexed for MEDLINE]Related articles

    12.

    Intentional overdose with insulin glargine and insulin aspart.

    Tofade TS, Liles EA.

    Pharmacotherapy. 2004 Oct;24(10):1412-8. Review.PMID: 15628838 [PubMed - indexed for MEDLINE]Related articles

    13.

    Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.

    Dashora UK, Sibal L, Ashwell SG, Home PD.

    Diabet Med. 2007 Apr;24(4):344-9. Epub 2007 Jan 12.PMID: 17298589 [PubMed - indexed for MEDLINE]Related articles

    14.

    Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.

    Campbell IW.

    Int J Clin Pract. 2005 Oct;59(10):1218-28. Review.PMID: 16178991 [PubMed - indexed for MEDLINE]Related articles

    15.

    No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes.

    Johanson EH, Jansson PA, Gustafson B, Sandqvist M, Taskinen MR, Smith U, Axelsen M.

    Diabetes Metab Res Rev. 2005 Jul-Aug;21(4):376-81.PMID: 15724236 [PubMed - indexed for MEDLINE]Related articles

    16.

    Metformin overdose.

    Brady WJ, Carter CT.

    Am J Emerg Med. 1997 Jan;15(1):107-8. No abstract available. PMID: 9002594 [PubMed - indexed for MEDLINE]Related articles

    17.

    Beneficial effects of nateglinide on insulin resistance in type 2 diabetes.

    Hazama Y, Matsuhisa M, Ohtoshi K, Gorogawa S, Kato K, Kawamori D, Yoshiuchi K, Nakamura Y, Shiraiwa T, Kaneto H, Yamasaki Y, Hori M.

    Diabetes Res Clin Pract. 2006 Mar;71(3):251-5. Epub 2005 Oct 7.PMID: 16214255 [PubMed - indexed for MEDLINE]Related articles

    18.

    Determination of the nateglinide polymorphism structure and the drug effect.

    Li G, Chen JY, Lü GL, Xu QW.

    Yao Xue Xue Bao. 2005 Oct;40(10):958-60. No abstract available. PMID: 16408818 [PubMed - indexed for MEDLINE]Related articles

    19.

    Postmarketing surveillance study of nateglinide in Japan.

    Taki H, Maki T, Iso T, Iwamoto K, Kajiura T.

    Adv Ther. 2005 Sep-Oct;22(5):513-26.PMID: 16418160 [PubMed - indexed for MEDLINE]Related articles

    20.

    Nateglinide with glibenclamide examination using the respiratory quotient (RQ).

    Harada S, Nomura M, Nakaya Y, Ito S.

    J Med Invest. 2006 Aug;53(3-4):303-9.PMID: 16953069 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity